



# Module 1 wrap up discussion

March 5, 2019


# Our path to evaluate FKBP12 ligands




*in silico* cloning; overexpress FKBP12  
lab day 1




purify and analyze FKBP12  
lab days 2 and 4




re-analyze screen data  
lab day 3



test FKBP12 and ligands  
in enzyme activity assay  
lab day 5



test ligands in FKBP12  
binding assay  
lab day 6



$$IC_{50} = X \mu M$$
$$\Delta T = Y ^\circ C$$

complete data analysis  
prioritize best ligands  
lab day 7

# Report for Module 1

scientific abstract

nature  
chemical biology

## A small molecule that binds Hedgehog and blocks its signaling in human cells

Benjamin Z Stanton<sup>1,2,7</sup>, Lee F Peng<sup>1-3,7</sup>, Nicole Maloof<sup>1</sup>, Kazuo Nakai<sup>2</sup>, Xiang Wang<sup>1</sup>, Jay L Duffner<sup>1</sup>, Kennedy M Taveras<sup>1</sup>, Joel M Hyman<sup>4</sup>, Sam W Lee<sup>5</sup>, Angela N Koehler<sup>1</sup>, James K Chen<sup>4</sup>, Julia L Fox<sup>6</sup>, Anna Mandinova<sup>5</sup> & Stuart L Schreiber<sup>1,2</sup>

**Small-molecule inhibition of extracellular proteins that activate membrane receptors has proven to be extremely challenging. Diversity-oriented synthesis and small-molecule microarrays enabled the discovery of robotnikinin, a small molecule that binds the extracellular Sonic hedgehog (Shh) protein and blocks Shh signaling in cell lines, human primary keratinocytes and a synthetic model of human skin. Shh pathway activity is rescued by small-molecule agonists of Smoothened, which functions immediately downstream of the Shh receptor Patched.**

# Report for Module 1

project summary

thorough summary of your data and figures with supporting text –  
include context so that a **scientifically literate reader** can understand  
the work and its broader implications

details related to the format and content are on the 20.109 wiki  
(example posted)

# Report for Module 1

## format and content

**Layout:** Portrait, not landscape.

**Font:** Arial 14pt for text; Arial 12pt for figure captions.

**Text** should be written as **bullet points**, not full sentences and paragraphs.

### Content details

**First page:** Title and Author information (section/color/names)

**Second page:** Abstract

**Body:** 8-12 pages (not including Title and Abstract pages). Recommended section lengths (including both text and figures):

**Background and Motivation:** 2 slides

Contents of Background and Motivation: The majority of this section will be bulleted text. Include schematic figures when appropriate.

**Results and Interpretation:** 5-8 slides

Contents of a Results and Interpretation slide: Top half: figure(s) with caption(s). Bottom half: bullet points that present and interpret the data. (Remember that captions should not contain interpretation.)

Figure presentation: In published research figures are rarely a full page in size; rather each plot is usually only 3 inches x 3 inches.

Present your Results and Interpretation such that the figure, caption, and interpretation bullet points **all fit on a single slide**. Remember that when you shrink a figure, you must make sure it remains legible.

**Implications and Future Work:** 1-2 slides

Contents of Implications and Future Work: This section will be bulleted text.

# Background and motivation

suggested topics or figures

Topic: Introduce how novel chemical probes for FKBP12 would enable biological engineering research

Topic: Introduce and discuss the utility of small-molecule microarrays (SMMs) to find putative ligands

Topic: Describe methodologies to evaluate putative ligands via FKBP12 binding and activity assays

Figure: Simplified schematic of '*Critical Path for Probe Discovery and Characterization*'

Topic: Discuss your experimental goal

Schematic: Experimental approach

# Results and Interpretation

suggested topics or figures

## Protein purification

Schematic: Experimental design

Topic: FKBP12 purification

Figure: Image of polyacrylamide gel

Figure: Graph or table displaying cell protein concentration

## Ligand characterization

Schematic: Experimental approach

Topic: Identification of positive hits from Spring 20.109 SMM data

Figure: Chemical structures for compounds tested

# Results and Interpretation

suggested topics or figures

## PPI'ase enzymatic assay

Schematic: Experimental design

Topic: Explain the enzymatic reaction that you evaluated (from Wiki)

Figure: Specific Activity calculation for your FKBP12

Figure: Activity plots for each condition tested: your FKBP12, Abcam FKBP12, different ligands, DMSO control


## DSF thermal shift assay

Schematic: Experimental approach

Topic: Thermal shift/DSF assay design, samples tested

Figure: Raw thermal shifts or first derivative data plots for each condition tested (see Wiki for great example of Rapamycin vs. DMSO comparison)


Figure: Combined class data set for Rapamycin to determine an apparent affinity constant



# An histidine covalent receptor and butenolide complex mediates strigolactone perception

Alexandre de Saint Germain<sup>1-6,14</sup>, Guillaume Clavé<sup>7-9,14</sup>, Marie-Ange Badet-Denisot<sup>7-9</sup>, Jean-Paul Pillot<sup>1-4</sup>, David Cornu<sup>10-12</sup>, Jean-Pierre Le Caer<sup>7-9</sup>, Marco Burger<sup>5,6</sup>, Frank Pelissier<sup>7-9</sup>, Pascal Retailleau<sup>7-9</sup>, Colin Turnbull<sup>13</sup>, Sandrine Bonhomme<sup>1-4</sup>, Joanne Chory<sup>5,6\*</sup>, Catherine Rameau<sup>1-4\*</sup> & François-Didier Boyer<sup>1-4,7-9\*</sup>

Strigolactone plant hormones control plant architecture and are key players in both symbiotic and parasitic interactions. They contain an ABC tricyclic lactone connected to a butenolide group, the D ring. The DWARF14 (D14) strigolactone receptor belongs to the superfamily of  $\alpha/\beta$ -hydrolases, and is known to hydrolyze the bond between the ABC lactone and the D ring. Here we characterized the binding and catalytic functions of RAMOSUS3 (RMS3), the pea (*Pisum sativum*) ortholog of rice (*Oryza sativa*) D14 strigolactone receptor. Using new profluorescent probes with strigolactone-like bioactivity, we found that RMS3 acts as a single-turnover enzyme that explains its apparent low enzymatic rate. We demonstrated the formation of a covalent RMS3-D-ring complex, essential for bioactivity, in which the D ring was attached to histidine 247 of the catalytic triad. These results reveal an undescribed mechanism of plant hormone reception in which the receptor performs an irreversible enzymatic reaction to generate its own ligand.



# An histidine covalent receptor and butenolide complex mediates strigolactone perception

Alexandre de Saint Germain<sup>1-6,14</sup>, Guillaume Clavé<sup>7-9,14</sup>, Marie-Ange Badet-Denisot<sup>7-9</sup>, Jean-Paul Pillot<sup>1-4</sup>, David Cornu<sup>10-12</sup>, Jean-Pierre Le Caer<sup>7-9</sup>, Marco Burger<sup>5,6</sup>, Frank Pelissier<sup>7-9</sup>, Pascal Retailleau<sup>7-9</sup>, Colin Turnbull<sup>13</sup>, Sandrine Bonhomme<sup>1-4</sup>, Joanne Chory<sup>5,6\*</sup>, Catherine Rameau<sup>1-4\*</sup> & François-Didier Boyer<sup>1-4,7-9\*</sup>

Strigolactone plant hormones control plant architecture and are key players in both symbiotic and parasitic interactions. They contain an ABC tricyclic lactone connected to a butenolide group, the D ring. The DWARF14 (D14) strigolactone receptor belongs to the superfamily of  $\alpha/\beta$ -hydrolases, and is known to hydrolyze the bond between the ABC lactone and the D ring. Here we characterized the binding and catalytic functions of RAMOSUS3 (RMS3), the pea (*Pisum sativum*) ortholog of rice (*Oryza sativa*) D14 strigolactone receptor. Using new profluorescent probes with strigolactone-like bioactivity, we found that RMS3 acts as a single-turnover enzyme that explains its apparent low enzymatic rate. We demonstrated the formation of a covalent RMS3-D-ring complex, essential for bioactivity, in which the D ring was attached to histidine 247 of the catalytic triad. These results reveal an undescribed mechanism of plant hormone reception in which the receptor performs an irreversible enzymatic reaction to generate its own ligand.

## summary table of data

**Table 1 | Thermodynamic and kinetic constants of ligands and probes toward RMS3**

Protein		RMS3						
Ligand	( $\pm$ )-GR24	( $\pm$ )-2'-epi-GR24	(+)-GR24	(-)-GR24	( $\pm$ )-Solanacol	( $\pm$ )-3'-Me-GR24	( $\pm$ )-4'-Desmethyl-2'-epi-GR24	( $\pm$ )-ABC
$K_d$ ( $\mu\text{M}$ )	22.0 $\pm$ 4.8	71.0 $\pm$ 15.2	15.7 $\pm$ 3.7	35.9 $\pm$ 3.6	137.1 $\pm$ 33.2	30.9 $\pm$ 5.2	295.7 $\pm$ 27.9	271.2 $\pm$ 29.8
$K_i$ ( $\mu\text{M}$ )	0.10 $\pm$ 0.07	0.23 $\pm$ 0.03	0.07 $\pm$ 0.01	5.17 $\pm$ 1.01	21.5 $\pm$ 2.6	n.d.	n.d.	28.8 $\pm$ 17.6
Protein		RMS3						
Probe	( $\pm$ )-GC242	(-)-GC242	(+)-GC242	( $\pm$ )-GC240	( $\pm$ )-GC486	DiFMU	( $\pm$ )-GC242	AtD14
$K_d$ ( $\mu\text{M}$ )	58.9 $\pm$ 9.6	82.6 $\pm$ 7.6	581.1 $\pm$ 194.3	74.1 $\pm$ 5.9	21.0 $\pm$ 1.4	19.9 $\pm$ 1.1	n.d.	n.d.
$K_{1/2}$ ( $\mu\text{M}$ )	0.49 $\pm$ 0.05	1.56 $\pm$ 0.32	17.42 $\pm$ 4.17	3.83 $\pm$ 1.80	n.d.	n.d.	1.19 $\pm$ 0.21	n.d.
$k_{\text{cat}}$ ( $\text{min}^{-1}$ )	0.012 $\pm$ 0.005	0.184 $\pm$ 0.017	0.136 $\pm$ 0.027	0.054 $\pm$ 0.015	n.d.	n.d.	0.030 $\pm$ 0.002	n.d.
$k_{\text{cat}}/K_{1/2}$ ( $\mu\text{M}^{-1} \text{min}^{-1}$ )	0.024	0.118	0.007	0.014	n.d.	n.d.	0.025	n.d.

Binding properties of RMS3 protein in the presence of different SL analogs were estimated by the apparent dissociation coefficients ( $K_d$ ) derived from intrinsic fluorescence measurements.  $K_i$  values were determined using a competition test with ( $\pm$ )-GC242.  $K_{1/2}$  and  $k_{\text{cat}}$  are pre-steady-state kinetic constants for RMS3 and AtD14 with different profluorescent probes. n.d., not determined.  $K_d$  values represent the mean  $\pm$  s.e.m. of two replicates and  $K_{1/2}$ ,  $k_{\text{cat}}$  and  $K_i$  values represent the mean  $\pm$  s.e.m. of three replicates.

# Implications and Future Work

Why is your work impactful and what would you do next?

**Topic:** Was your FKBP12 pure or active? If not, provide a putative explanation and explain how you might change the protocol if given another shot.

**Topic:** Did you have any compounds that confirmed as binders? Is this consistent with similar research? If not, provide a putative explanation.

**Topic:** How might you further validate that your SMM positive are binders and measure affinity values for the protein-ligand interaction? Other methods to complement DSF?

**Topic:** How can you use your FKBP12 binders to further research focused on this protein?

**Topic:** How might this method be improved?

**Topic:** How might this assay be used in the clinic? in industry?